Abstract
The follow-up of patients after coronary artery bypass grafting is of paramount importance for a good control of chronic ischemic coronary disease. The non-pharmacological treatment should be approached in an assertive way with the patients, placing it at the center of the problem participating in the health process and definitely understanding the disease. Pharmacological clinical treatment involves modern drugs, widely studied, tested and available worldwide, which need to be used at the maximum tolerated dose in order to achieve the goals disseminated by the guidelines with a view to improving morbidity and mortality and quality of life of patients.
Reference96 articles.
1. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics—2019 update: A report from the American Heart Association. Circulation. 2019;139:56-e528
2. Reza M et al. Cardiovascular disease projections in the United States based on the 2020 census estimates. Journal of the American College of Cardiology. 2022;80(6):565-578
3. Mehta D. Integrative medicine and cardiovascular disorders. Primary Care. 2017;44(2):351-367
4. Wong ND et al. Metabolic syndrome, diabetes, and incidence and progression of coronary calcium. JACC: Cardiovascular Imaging. 2012;5:358-366
5. Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. The New England Journal of Medicine. 2015;372:1333-1341